Lowering Blood Pressure Curing the Kidneys ~

Lowering Blood Pressure Curing the Kidneys ~

Join the Revolution in Kidney Care

Postpone Dialysis. Reduce Blood Pressure. Save Lives and Billions.
Curespec offers the only treatment for revitalizing kidneys, providing patients with Chronic Kidney Disease (CKD) and Hypertension a chance to improve and extend their lives.

We invite you to become a part of this revolutionary and humanitarian venture.

Why Invest in Curespec?

Groundbreaking Technology:
Curespec has developed a patent-protected shockwave device to treat CKD and hypertension, offering a non-invasive and cost-effective solution.

Proven Support:
The American National Institute of Health (NIH) recognized the importance of our innovation and funded its first study.

Massive Market Opportunity:
The global dialysis market is projected to reach $114 billion by 2029. Our device can significantly reduce healthcare costs by delaying dialysis and improving kidney function.

Measurable Impact:

Lowers blood pressure by 10-15 mmHg.

Delays dialysis need by at least 12 months.

Improves kidney function by 5%.

Saves up to 80% in costs compared to dialysis.

Postpones dialysis, reduces blood pressure and saves billions to healthcare systems

We are the only ones offering patients suffering from CKD and Hypertension a treatment for the revitalization of the kidneys which will improve and extend their life.

We invite you to take part in this revolutionary and humanitarian venture.

    • Pre-clinical study was carried out in MAYO Clinic, Rochester US

    • Five articles were published following the study in the US

    • A preliminary study in humans was carried out at the University of Osaka-Japan.

    • Patent registration

    • Obtaining CE Mark certification

    • Continued human research at SZMC (Sha’are Zedek hospital – Jerusalem - in progress

    • Continued human research in the Far East (Philippines and India) – in progress

    • Beginning of a multi-center RCT study in Israel, Europe and the USA with approximately 200 patients – in progress

    • Submission of first applications for the REIMBURSEMENT code in the leading European countries

    • First publications from the clinical study

    • Continuation of the multicenter study in Europe, Israel and the USA.

    • Submission for FDA approval

    • Obtaining the REIMBURSEMENT code in some European countries

    • Start of sales in Europe

    • Completion of the mobilization for the multi-center study – about 200 patients

    • NASDAQ listing/IPO

    • Increasing sales volume

    • Transition to profitability

    • Preparation for issuance or purchase by a major medical device company

Timeline to markets and IPO

Curespec's Advantages

Delays Dialysis
Reduces the financial and emotional burden on patients and healthcare systems.

Cost-Effective Solution
Saves healthcare systems billions of dollars by reducing dialysis expenses.

Life-Changing Outcomes
Improves quality of life for millions suffering from CKD and hypertension.

Investments starting from $200,000

Want to speak with a Curespec manager?
Send us your contact information and we’ll
​ensure a representative gets in contact with you: